Ortonne J-P, Kaufmann R, Lecha M, Goodfield M
Service de Dermatologie, Hôpital de l'Archet, Nice, France.
Dermatology. 2004;209(4):308-13. doi: 10.1159/000080854.
A two-compound product containing calcipotriol 50 microg/g and betamethasone dipropionate 0.5 mg/g (Daivobet, Dovobet) has been demonstrated to be an effective, once daily, treatment for psoriasis vulgaris.
To compare the efficacy and safety of treatment with the two-compound product for 4 weeks followed by calcipotriol for 4 weeks, with that of tacalcitol for 8 weeks in patients with stable psoriasis vulgaris.
501 patients were randomised to double-blind treatment with the two-compound product followed by calcipotriol 50 microg/g once daily, or to tacalcitol 4 microg/g once daily.
Treatment with the two-compound product/calcipotriol was significantly more effective than tacalcitol in terms of mean percentage PASI reduction (65.0 vs. 33.3% at week 4 and 59.0 vs. 38.4% at week 8; p < 0.001 for both).
A treatment regimen comprising calcipotriol/betamethasone ointment (Daivobet) for 4 weeks followed by calcipotriol for 4 weeks is superior to tacalcitol ointment for 8 weeks in patients with psoriasis vulgaris.
一种含有50微克/克骨化三醇和0.5毫克/克二丙酸倍他米松的复方产品（达力士倍他米松，得肤宝）已被证明是治疗寻常型银屑病的一种有效的每日一次用药。
比较在寻常型银屑病稳定期患者中，先用该复方产品治疗4周，再用骨化三醇治疗4周与用他卡西醇治疗8周的疗效和安全性。
501例患者被随机分为两组，一组接受该复方产品的双盲治疗，随后每日一次使用50微克/克骨化三醇；另一组每日一次使用4微克/克他卡西醇。
就银屑病面积和严重程度指数（PASI）平均降低百分比而言，复方产品/骨化三醇治疗比他卡西醇治疗显著更有效（第4周时分别为65.0%对33.3%，第8周时为59.0%对38.4%；两者p均<0.001）。
对于寻常型银屑病患者，一种治疗方案为先使用骨化三醇/倍他米松软膏（达力士倍他米松）治疗4周，随后使用骨化三醇治疗4周，优于使用他卡西醇软膏治疗8周。
Zotero 插件